Haemonetics (NYSE:HAE) announced today that Josep Llorens, EVP of global manufacturing and supply chain, plans to retire.

Central Pacific Bank Trust Division lowered its holdings in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 10.8% in ...

Haemonetics has announced the upcoming retirement of Josep Llorens, their Executive Vice President of Global Manufacturing and Supply Chain, effective July 11, 2025. Mr. Llorens will remain in his ...

Haemonetics Corporation’s HAE growth in the fiscal second quarter of 2025 can be attributed to the strong potential of the ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Abbott (ABT). But which of these two stocks offers value investors a better bang ...

To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Haemonetics said Tuesday it agreed to sell its whole-blood business to Italy’s GVS for up to $67.1 ...

Analyst Michael Petusky from Barrington maintained a Buy rating on Haemonetics (HAE – Research Report) and keeping the price target at $108.00. Don't Miss our Black Friday Offers: Michael ...

Haemonetics' strong hospital services growth and innovative products are promising, but regional headwinds, declining plasma revenue, and high debt levels warrant a Hold rating. The company saw a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

JPMorgan analyst Rohin Patel initiated coverage of Haemonetics (HAE) with an Overweight rating and $116 price target Haemonetics has “multiple shots on goal” that should support sales ...

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma ...